Weekly AdvaMed® COVID-19 Testing Registry Update: Over 180 Million Molecular Tests Shipped Nationwide

WASHINGTON, D.C. – New data from AdvaMed®’s COVID-19 Diagnostic Supply Registry reveals that total U.S. shipments of COVID-19 molecular diagnostic tests have reached over 180 million. A breakdown of the data shows that innovative diagnostics companies are shipping, on average, over 1.3 million molecular tests each day.

Unveiled July 21, AdvaMed®’s Registry compiles information from leading diagnostics companies along with publicly available data on daily tests performed to create a centralized and standardized COVID-19 diagnostic supply registry. The registry provides weekly state- and national-level updates on the number of molecular, and serology (antibody) tests shipped in the U.S. to help state and federal governments in their pandemic responses. AdvaMed® and AdvaMedDx®, the association’s division of diagnostics companies, developed the National Testing Registry in partnership with 13 commercial diagnostics manufacturers: Abbott, BD, bioMérieux, Bio-Rad, Beckman Coulter, Cepheid, Hologic, Ortho Clinical Diagnostics, QIAGEN, Roche Diagnostics, Sekisui Diagnostics, Siemens Healthineers, and Thermo Fisher Scientific. 

# # #

AdvaMed® member companies produce the medical devices, diagnostic products and health information systems that are transforming health care through earlier disease detection, less invasive procedures and more effective treatments. AdvaMed® members range from the largest to the smallest medical technology innovators and companies. For more information, visit www.advamed.org.

AdvaMedDx® member companies produce innovative, safe and effective in vitro diagnostic tests that facilitate evidence-based medicine, improve quality of patient care, promote wellness, enable early detection of disease and reduce overall health care costs. Functioning as an association within AdvaMed®, AdvaMedDx® is dedicated to the issues facing in vitro diagnostic companies both in the United States and abroad. For more information, click here.